Piramal Pharma Share Price

NSE
PPLPHARMA •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Piramal Pharma Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
135.94% Gain from 52W Low
22.9
TTM PE Ratio
High in industry
789.1
Price to Book Ratio
Above industry Median
4.5
Dividend yield 1yr %
Low in industry
0.04
TTM PEG Ratio
PEG TTM is much higher than 1
5.9

Piramal Pharma Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Piramal Pharma Ltd Quarterly Revenue

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
2241.75 Cr
1951.14 Cr
2552.36 Cr
1958.57 Cr
1911.38 Cr

Piramal Pharma Ltd Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021
8346.55 Cr
7306.66 Cr
6834.9 Cr
6479.01 Cr

Piramal Pharma Ltd Quarterly Net Profit/Loss

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
5.33 Cr
-111.04 Cr
89.23 Cr
-3.84 Cr
-14.09 Cr

Piramal Pharma Ltd Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021
-41.67 Cr
-240.79 Cr
316.93 Cr
787.79 Cr

Piramal Pharma Ltd shareholding Pattern

Promoter
35%
Foreign Institutions
31.7%
Mutual Funds
11.2%
Domestic Institutions
13.8%
Public
19.1%
Promoter
35%
Foreign Institutions
31.4%
Mutual Funds
10.1%
Domestic Institutions
13%
Public
20.2%
Promoter
35%
Foreign Institutions
30.6%
Mutual Funds
9%
Domestic Institutions
12.1%
Public
21.9%
Promoter
35%
Foreign Institutions
32.5%
Mutual Funds
6.3%
Domestic Institutions
9.7%
Public
22.4%
Promoter
35%
Foreign Institutions
32.4%
Mutual Funds
3.8%
Domestic Institutions
8%
Public
24.2%
Promoter
34.8%
Foreign Institutions
35%
Mutual Funds
0.9%
Domestic Institutions
5.5%
Public
24.3%

Piramal Pharma Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
15
Bearish Moving Averages
1
5Day EMA
267.40
10Day EMA
263.40
12Day EMA
262.50
20Day EMA
259.70
26Day EMA
257.40
50Day EMA
246.10
100Day EMA
223.40
200Day EMA
193.20
5Day SMA
269.90
10Day SMA
259.30
20Day SMA
262.40
30Day SMA
260.50
50Day SMA
246.00
100Day SMA
217.50
150Day SMA
195.80
200Day SMA
180.00
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
2819865 Rs
10812060 Rs
Week Rs
2892291 Rs
14462814 Rs
Month Rs
2400622 Rs
13081390 Rs
Resistance & Support
271.92
Pivot
Resistance
First Resistance
281.48
Second Resistance
288.82
Third Resistance
298.38
Support
First Support
264.58
Second support
255.02
Third Support
247.68
Relative Strength Index
59.79
Money Flow Index
63.04
MACD
5.10
MACD Signal
4.40
Average True Range
13.69
Average Directional Index
24.19
Rate of Change (21)
-0.60
Rate of Change (125)
87.90

Piramal Pharma Ltd Company background

Founded in: 2020
Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through endtoend manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling overthecounter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. Piramal Pharma Solution provides integrated drug discovery, development, and manufacturing services for both drug substances, i.e. active pharmaceutical ingredients (APIs) and drug products, i.e. formulations across the life cycle of a molecule, from discovery and clinical development to commercial launch. In addition, the Company has a joint venture (Allergan India Private Limited) with Allergan(now AbbVie), one of the market leaders in ophthalmology in the Indian formulations market. PPL holds 49% of the paidup equity share capital in the joint venture. Further, PPL has a minority investment of 33.33% in Yapan Bio that operates in the biologics/ biotherapeutics and vaccine segments. The Company is among the leading players in India in the selfcare space, with established brands like Saridon, Supradyn, Lacto Calamine, Littles, Tetmosol, iPill and Polycrol.Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines. It has a global footprint with manufacturing capabilities across 15 facilities spanning across India, US, the UK and Canada. It also has global distribution network in over 100 countries. The Companys global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions.In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL).In October 2020, the Company received growth equity investment from the Carlyle Group. In It acquired 100% stake in Convergence Chemicals Private Limited (CCPL). It announced expansion for antibody drug conjugates at its Grangemouth (UK) facility and expansion of drug substance capabilities at its Riverview facility (USA).In 2021, it acquired Hemmo Pharmaceuticals Private Limited (HPPL), into the development and manufacturing of peptide APIs. On 7th October 2021, the Composite Scheme of Arrangement, which was entered into between the Company, Piramal Pharma Limited (PPL), Convergence Chemicals Private Limited (CCPL), Hemmo Pharmaceuticals Private Limited (HPPL), PHL Fininvest Private Limited (PFPL) and their respective shareholders and creditors for demerger of Pharma Business from Piramal Enterprises Limited (PEL) to PPL, amalgamation of CCPL and HPPL (both being wholly owned subsidiaries of PPL) into PPL and the amalgamation of PFPL (a wholly owned subsidiary of PEL) into PEL was effective from August 18, 2022.In consideration for the demerger, the equity shareholders of PEL as on the demerger record date received 4 equity shares of face and paidup value of Rs 10 each of the Company for every 1 equity share of face and paidup value of Rs 2 each held in PEL. i.e. 4:1. Accordingly, the Company was listed on the Stock Exchanges, BSE Limited (BSE) and National Stock Exchange of India Limited NSE) onOctober 19, 2022. In 2022, the Company acquired minority stake in Yapan Bio Private Limited, an IndiaBased CDMO providing expertise in biologics and vaccines. It launched 26 New products and 37 new SKUs during FY 2023.
Read More

Piramal Pharma Ltd FAQs

Piramal Pharma Ltd shares are currently priced at 269.8 on NSE and 269 on BSE as of 12/5/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Piramal Pharma Ltd [PPLPHARMA] share was 113.53. The Piramal Pharma Ltd [PPLPHARMA] share hit a 1-year low of Rs. 114.35 and a 1-year high of Rs. 307.9.

The market cap of Piramal Pharma Ltd is Rs. 36345.38 Cr. as of 12/5/2024 12:00:00 AM.

The PE ratios of Piramal Pharma Ltd is 56.52 as of 12/5/2024 12:00:00 AM.

The PB ratios of Piramal Pharma Ltd is 5.17 as of 12/5/2024 12:00:00 AM

The Mutual Fund Shareholding was 11.21% at the end of 12/5/2024 12:00:00 AM.

You can easily buy Piramal Pharma Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -